Lion Biotechnologies, Inc. (LBIO)

Oncology Corporate Profile

Stock Performance

5.6900
-0.1600

HQ Location

21900 Burbank Blvd., Third Floor
Woodland Hills, CA 91367

Company Description

Lion Biotechnologies, Inc. is engaged in the development of T-cells and engineered T-cells for the treatment of various cancers. The company's lead product candidate is a ready-to-infuse autologous T-cell therapy utilizing tumor-infiltrating lymphocytes (TILs) for the treatment of patients with Stage 4 metastatic melanoma, and is based on a clinical CRADA with the National Cancer Institute.

Website: http://lbio.com

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
NCI/Lion Bio(TIL) tumor infiltrating lymphocytesMelanomaII
NCI/Lion Bio (+ vemurafenib)(TIL) tumor infiltrating lymphocytesMelanomaI

View additional information on product candidates here »

Source: http://lbio.com

Recent News Headlines

5/22/2017 12:18 pm

5/22/2017 12:18 pm

5/22/2017 12:18 pm

5/22/2017 12:18 pm

5/22/2017 06:18 am

5/22/2017 06:18 am

5/22/2017 06:18 am

5/22/2017 06:18 am

5/22/2017 06:18 am

5/19/2017 06:18 pm

5/19/2017 06:18 pm

5/19/2017 06:18 pm

5/19/2017 06:18 pm

5/18/2017 12:18 pm

5/18/2017 12:18 pm

5/18/2017 06:18 am

5/18/2017 06:18 am

5/18/2017 06:18 am

5/18/2017 06:18 am

5/18/2017 06:18 am

5/17/2017 12:18 pm

5/16/2017 06:18 am

5/15/2017 12:18 pm

5/15/2017 12:18 pm

5/15/2017 06:18 am